| Name | Title | Contact Details |
|---|
Opus is a technology-driven growth company in the vehicle inspection and intelligent vehicle support markets. The company has a strong focus on customer service and innovative technology within emission and safety testing and intelligent vehicle support.
Executive Meeting Center-Sheaton Colonial Boston North Hotel is a Wakefield, MA-based company in the Business Services sector.
Grey Rock Energy Partners is a Dallas-based private equity firm. We build a Diversified, Direct Investment Portfolio with Experienced Operators.
The Nonprofit Finance Fund (NFF) is a nonprofit organization based in New York City, founded in 1980 by Clara Miller. Originally established as the Energy Conservation Fund, it has evolved to focus on supporting community wealth and well-being through lending, consulting, and advocacy, with a strong commitment to advancing racial equity. NFF offers various services to strengthen nonprofit organizations. Its lending services provide financing options to help nonprofits access capital for projects, while consulting services assist them in managing finances and improving operations. Additionally, NFF advocates for equitable funding systems and shares valuable insights through webinars, reports, and other resources. With offices in New York City, Boston, Philadelphia, Oakland, and Los Angeles, NFF serves a diverse range of nonprofits across sectors such as education, health, and civil rights. The organization collaborates with major grantmakers to further its mission and has received significant funding to support community development initiatives.
TIXiMED, Inc. is focused on developing and commercializing TXNIP inhibiting medication as a first-of-its-kind oral therapeutic for Type 1 and Type 2 diabetes. TIXiMED is the exclusive license holder for the patent (composition of matter and method of use) surrounding TIX100, a novel small molecule that normalizes pancreatic beta cell TXNIP, a detrimental protein elevated in Type 1 and Type 2 diabetes. Increased TXNIP causes pancreatic islet dysfunction and death of insulin-producing beta cells and thereby contributes to the development and progression of diabetes. Diabetes affects more than half a billion people worldwide. Those affected by Type 1 diabetes are dependent on multiple daily insulin injections or continuous insulin infusions to stay alive and manage their blood sugar. Oral anti-diabetic drugs are only approved for Type 2 diabetes, but can be associated with multiple side effects, underlining the need for novel and better oral diabetes medications for Type 1 and Type 2 diabetes. TXNIP inhibition has recently been demonstrated to be an effective and safe therapeutic approach in adults and children with recent onset Type 1 diabetes and TIX100 shows beneficial, anti-diabetic effects in 4 different mouse models. Advantages of TIX100 include oral availability, no associated hypoglycemia or weight gain, potent inhibition of detrimental TXNIP in human islets, and a favorable pharmacokinetic and safety profile. In addition, TIX100 inhibits excessive glucagon secretion and hepatic glucose production and protects against fatty liver. Thus, TIX100 holds promise for durable, weight-neutral improvement in glycemic control in Type 1 and Type 2 diabetes by targeting common underlying pathology and promoting patients own islet cell health.